ERGOMED

News

London, UK, 3 April 2017

Ergomed notes co-development partner Asarina Pharma announces successful topline data for its Phase IIa Clinical Study with Sepranolone in Premenstrual Dysphoric Disorder (‘PMDD’)

London, UK – 3 April 2017: Ergomed plc (LSE: ERGO) (‘Ergomed’ or ‘the Company’), a company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, notes co-development partner, Asarina Pharma, has today announced the publication of its phase IIa clinical study with Sepranolone in…


London, UK, 28 March 2017

Unaudited Preliminary Results for the year ended 31 December 2016

Top line revenue growth of 30%

Gross profit up 43%

New business won in 2016 increased 50% to £42 million

Contracted backlog at 1 January 2017 of £70 million

Multiple corporate milestones achieved in 2016

Post year-end positive Phase II results announced from insomnia study

London,…


London, UK, 21 March 2017

Notice of Preliminary Results

London, UK – 21 March 2017: Ergomed plc (LSE: ERGO) (‘Ergomed’ or ‘the Company’), a company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, will announce its unaudited preliminary results for the year ended 31 December 2016 on Tuesday 28 March 2017.


London, UK, 20 March 2017

Ergomed Initiates Phase II study of topical PeproStat in Intraoperative surgical haemostatis

Headline data expected in Q1 2018

 British company’s invention for surgical bleeding advances in clinical development

London, UK – 20 March 2017: Ergomed plc (LSE: ERGO) (‘Ergomed’ or ‘the Company’), a company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, is…


London, UK, 20 February 2017

Ergomed notes co-development partner Modus Therapeutics successfully raises SEK 32 million (£2.9m)

London, UK – 20 February 2017: Ergomed plc (LSE: ERGO) (‘Ergomed’ or ‘the Company’), a company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, is pleased to note that its co-development partner Modus Therapeutics has today announced their successful financing round, raising SEK 32 million…


Page 5 of 19« First...34567...10...Last »
Translate »